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It is increasingly common in oncology practice to perform tumour sequencing using large cancer panels. For pathogenic
sequence variants in cancer susceptibility genes identified on tumour-only sequencing, it is often unclear whether they are of
somatic or constitutional (germline) origin. There is wide-spread disparity regarding both the extent to which systematic
‘germline-focussed analysis’ is carried out upon tumour sequencing data and for which variants follow-up analysis of a germline
sample is carried out. Here we present analyses of paired sequencing data from 17 152 cancer samples, in which 1494
pathogenic sequence variants were identified across 65 cancer susceptibility genes. From these analyses, the European Society
of Medical Oncology Precision Medicine Working Group Germline Subgroup has generated (i) recommendations regarding
germline-focussed analyses of tumour-only sequencing data, (ii) indications for germline follow-up testing and (iii) guidance on
patient information-giving and consent.
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Introduction
Tumour testing, until recently, typically comprised genotyping of
specific hotspot mutations in oncogenes. These analyses seldom
gave insights into patient germline status [1, 2]. Over the last
5 years, evolution of next-generation sequencing (NGS) technol-
ogy, growth in molecular oncology, emergence of molecularly
stratified basket/umbrella trials and vigorous marketing from
commercial providers, have fuelled expansion of ‘large’ tumour
sequencing panels targeting the full coding region of hundreds of
genes [3–5]. Whilst paired tumour-germline analysis may be car-
ried out in major academic cancer centres, tumour-only analysis
is the more typical current clinical standard [6].
As well as influencing cancer management and therapy, a sub-
stantial proportion of genes included on these large tumour pan-
els confer heritable predisposition to cancer, the so-called cancer
susceptibility genes (CSGs). A subset of variants identified in
CSGs are ‘pathogenic’ that is when present in the constitutional
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DNA, they will confer an elevated risk of developing one or more
cancer types. When such a variant is detected in a tumour, it is
unclear whether the variant is constitutional in origin (i.e. is pre-
sent in all or most tissues, including the germline) or it has been
somatically acquired (i.e. not in the germline but present in the
tumour 6 surrounding tissue). We refer to these as ‘tumour-
detected pathogenic variants of potential germline origin’, or ‘tu-
mour-detected pathogenic variants’.
Having identified that clinical practice in this area is widely dis-
parate, the European Society of Medical Oncology (ESMO)
Precision Medicine Working Group (PMWG) convened a sub-
group tasked with addressing germline management of tumour-
detected pathogenic variants, specifically:
(i) to identify the key issues relevant to laboratory and clinical
management,
(ii) to undertake analyses of relevant tumour and germline
data,
(iii) to generate consensus recommendations applicable in rou-
tine clinical-laboratory services regarding:
a. extent of germline-focussed analyses to be carried out
as routine,
b. when follow-up testing in a germline sample should be
undertaken,
c. patient information and consent.
Key issues relevant to germline-focussed tumour analysis:
The ESMO PMWG germline subgroup identified and
considered the following issues within their analyses and
recommendations:
• ‘On-tumour’ and ‘Off-tumour’ associations of gene with
tumour type
CSGs have been established, through prior research, as conferring
predisposition to specific tumour types; these associations we here-
after refer to as ‘on-tumour’. Hence, for BRCA1, a pathogenic vari-
ant identified in a breast tumour would be described as on tumour,
as presence of a germline BRCA1mutation confers elevated risk of
breast cancer. A BRCA1 pathogenic variant identified in a testicular
seminoma would be defined as ‘off-tumour’ as presence of a germ-
line BRCA1 mutation does not confer elevated risk of testicular
seminoma. Such a finding off-tumour would typically be termed a
‘secondary’ finding (if sought deliberately), or an ‘incidental’ find-
ing (if happened upon by chance during data review) [7].
• Clinical Actionability
Quantification of ‘clinical actionability’ for pathogenic var-
iants in CSGs has not been formally established but would widely
be agreed to encompass the penetrance (risk) of the associated
cancers, the ‘severity’ of the cancer and the availability of clinical
management options that mitigate the increased cancer risk
(screening, surgical prophylaxis, chemoprophylaxis and lifestyle
modification), along with the quality of evidence underpinning
each of these estimates [8].
For more frequently detected CSGs such as BRCA1/BRCA2/
MLH1/MSH2, evidence regarding cancer risk and the impact of
screening/interventions are relatively well established. For less fre-
quently detected CSGs, e.g. FLCN or FH, whilst robust evaluations
of clinical and economic impact are lacking, clinical management
is relatively consistent. For other CSGs such asDICER1 and BAP1,
evidence regarding penetrance and efficacy of interventions is
sparse andmanagement varies widely between centres.
The American College of Medical Genetics (ACMG) has
assembled a set of 25 CSGs of higher actionability for which they
have advised analysis for and return of pathogenic variants, re-
gardless of context of ascertainment [7, 9, 10].
An additional aspect of actionability relates to the impact on
management of the current cancer of a germline pathogenic vari-
ant. For example, identification of a germline BRCA1 pathogenic
variant in the on-tumour setting (breast or ovarian cancer) may
influence the choice of chemotherapy (platinum), eligibility for
targeted agents (PARP inhibitors) and/or primary surgical man-
agement (bilateral mastectomy in localised unilateral disease). In
genomically selected basket trials the germline status may influ-
ence eligibility for targeted drugs even in the off-tumour setting.
However, for many CSGs, identification of a germline pathogenic
variant has no impact onmanagement of a cancer once diagnosed
in the on- or off-tumour setting.
• Penetrance (risk) of cancer
Early estimates of cancer penetrance (risk) for CSGs were typ-
ically derived from linkage analysis using large multicase families.
Subsequent studies based on ascertainment from more modest
family clusters or unselected incident cancer cases have revealed
progressively lower estimates of penetrance for many CSGs.
Analyses of population data suggest penetrance may be lower still
if the germline pathogenic variant is ascertained completely ag-
nostic to phenotype [11]. Impact of preventive clinical interven-
tions will be predicated on the estimates of penetrance used for
the clinical or cost-effectiveness analyses.
• Tumour heterogeneity and contamination with normal
tissue
A heterozygous germline pathogenic variant in a CSG would
be anticipated to be present in 50% of alleles across body tissues,
including a tumour. On occasion, the variant allele frequency
(VAF) of a somatically-acquired mutation may exceed 50% due
to Loss of Heterozygosity of the opposite allele or tumour aneu-
ploidy. Most typically, somatic variants are detected at VAF
<50% due to a combination of clonal heterogeneity, contamin-
ation with lymphocytes/non-tumour cells and/or tumour aneu-
ploidy. It is important to note that compared with hybrid-
capture-based NGS strategies such as the one used for this ana-
lysis, PCR-based NGS strategies may not yield as consistent a
VAF, especially in FFPE specimens with poor DNA quality and
yield.
• Threshold for triggering germline follow-up testing
To control the volume of germline tests triggered, we required
a working threshold of ‘likelihood of germline origin’.
Historically, a threshold of 10% (based on personal and/or family
history of cancer) has widely been adopted in the UK National
Health Service for BRCA1/2 detection on clinical testing [12].
• Workflows, logistics and cost
Tumour molecular genetic analysis is frequently carried out in
molecular pathology laboratories geographically or administra-
tively distinct from those offering germline testing for CSGs.
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Resources in these molecular pathology laboratories are focussed
on interpretation of somatic genetics and expertise in germline
interpretationmay be lacking [13].
• Consent and patient education
Explicit consent is not routinely sought ahead of molecular
genetic analysis of the tumour, being a test undertaken alongside
histopathological examination to characterise the malignant tis-
sue in order to inform immediate management. Furthermore,
while tumour testing for treatment selection is most often
requested by oncologists, some molecular genetic tumour tests
are only initiated downstream of patient contact once the path-
ologist has carried out histological examination.
Conversely, a germline pathogenic CSG variant is often not
relevant for current cancer management, but may have implica-
tions for future health, family members, reproductive decision-
making and insurance. Accordingly it remains conventional
practice that explicit information and consent-taking precede
such analyses [14, 15].
Methods
ESMO PMWG germline subgroup
The Germline Subgroup convened by the ESMO PMWG comprised rep-
resentation from medical oncology, surgical oncology, clinical cancer
genetics, molecular pathology andmedical law. The Groupmet five times
to develop these recommendations (supplementary note, available at
Annals of Oncology online).
Case series
We utilised the largest available dataset of paired tumour-normal
sequencing, comprising 17 152 unselected cancer patients who presented
to Memorial Sloan Kettering Cancer Center between 2014 and 2017 in
whom clinical sequencing of both germline (blood) and tumour samples
had been successfully carried out using the MSK-IMPACT assay (the
MSK dataset) [4, 16–18]. All patients in this cohort had consented to
somatic and/or germline testing in the context of tumour-normal
sequencing using an institutional review board-approved protocol. For
the purpose of this analysis, all genetic data were anonymised.
Sequencing
Samples were sequenced to a median depth of 741 (tumour) and 470
(normal). Tumour samples exhibiting somatic hypermutation (defined
as >95th percentile of mutational burden) were analysed separately. All
patients received clinical MSK-IMPACT sequencing using either the first
or generation of the panel design interrogating 341 and 410 genes, re-
spectively. Data were extracted for 65 genes associated with germline sus-
ceptibility to invasive cancers. For 64 genes, the mode of inheritance was
autosomal dominant; MUTYH (autosomal recessive) was also included
on account of being on the ‘ACMG secondary findings gene list’ (supple-
mentary Table S1, available at Annals of Oncology online) [7].
Calling and variant classification
Joint variant calling was carried out in the tumour and the germline sam-
ples to generate optimal somatic calls. These were summed with the
germline-only calls to generate tumour variant frequencies [16, 17].
Variants retained for analysis were those predicted to cause protein trun-
cation in genes acting via loss-of-function and/or classified as germline
4-Likely Pathogenic or 5-Pathogenic (any star rating) based on the
ClinVar variant classification resource [19]. We excluded low penetrance
alleles assigned within ClinVar as ‘risk-factors’, such as APC c.3920T>A
(p.Ile1307Lys) and VHL c.598C>T (p.Arg200Trp). Inclusion of founder
mutations did not substantially alter germline conversion rates for the re-
spective genes (BRCA1, BRCA2, ATM) and these founder mutations
were therefore retained for subsequent analyses (supplementary Table
S2, available at Annals of Oncology online).
Gene annotation
A panel of five clinical (medical) geneticists specialising in cancer suscep-
tibility was convened (supplementary note, available at Annals of
Oncology online). Annotation was carried out independently for the 65
genes for (i) association with each individual cancer type [20], (ii) action-
ability (high/non-high), (iii) penetrance [high (RR> 4)/intermediate
(RR¼ 2–4)] [21] and (iv) robustness of implication pathogenic variants
in cancer susceptibility (clinical—grade or not). A status was assigned to
each gene based on the majority decision (supplementary Table S1, avail-
able at Annals of Oncology online).
High-actionability CSGs (HA-CSGs) were defined as those of a level of
actionability by which return of pathogenic germline variants would be
appropriate in the off-tumour as well as on-tumour context. We estab-
lished as a set of HA-CSGs, the 25 genes recommended for secondary
findings by the ACMG and identified five additional genes as being of
equivalent actionability to these 25 (PALB2, RAD51C, RAD51D, BRIP1,
SDHA). These genes are under current review for inclusion in the ACMG
secondary findings gene list [22–26].
From the remaining 35 genes, we established a set of 27 ‘standard-
actionability’ genes (SA-CSGs), namely those of high penetrance, for
which the actionability of monoallelic pathogenic variants was agreed to
be ‘clinical grade’, for which return of pathogenic germline variants in
the on-tumour context was agreed to be appropriate.
Calculation of germline conversion rate and
clinical recommendations
We defined a metric of ‘germline conversion rate’ (number of pathogenic
variants of true germline origin 100/total number of tumour-detected
pathogenic variants), which we calculated for each gene (i) for all genes
and (ii) stratified by gene actionability, context (on-tumour/off-tumour)
and/or patient age. We recommended for germline follow-up only genes
(i) of high/standard actionability (ii) for which a total of2 mutations of
true germline origin were detected across relevant tumour types (iii) for
which the germline conversion rate exceeded 10% for that group defined
by context and patient characteristics.
Results
Gross analyses of paired tumour-germline data
In total, 17 152 tumour-germline pairs were successfully analysed
of which 830 were excluded due to somatic hypermutation. The
remaining 16 322 paired samples were distributed by tumour type
as per supplementary Table S3, available at Annals of Oncology on-
line. Across the 65 genes analysed in 16 322 tumours, in total
1 997 499 tumour variants were identified (of which 1 959 587
were of true germline origin) (Table 1). Removal of common poly-
morphisms [1% minor allele frequency (MAF)] reduced the
number of tumour variants to 79 342 (of which 53 388 were of true
germline origin). We then applied an automated variant ‘patho-
genicity filter’, retaining only variants predicted to cause loss of
function of the protein and/or classified in ClinVar as Likely
Pathogenic (class 4) or Pathogenic (class 5). A total of 17 075
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tumour-detected pathogenic variants were retained [of which
1494 (8.7%) were of true germline origin]. Having examined the
distribution of tumour-detected VAF for variants of true germline
origin, we then removed variants of tumour VAF< 0.3 (SNVs) or
VAF <0.2 (small insertions/deletions) (Figure 1). Application of
this ‘VAF filter’ reduced the number of tumour-detected patho-
genic variants from 17 075 to 9222, and true germline pathogenic
variants from 1494 to 1442 (Figure 2).
Analyses by gene: actionability and on/off tumour
association
Wewent on to examine germline conversion rate stratified by gene
actionability, context (on-tumour/off-tumour) and/or patient
age. We first examined the germline conversion rate in the 30 HA-
CSGs. In the off-tumour setting, 19 of 30 genes surpassed the 10%
threshold (Figure 3A). In the on-tumour setting, for 14 of those 19
genes the ‘germline conversion rate’ was likewise >10% and for 4
genes (SDHAF2, SDHD, SDHC and RAD51D) no pathogenic se-
quence variants were observed in associated tumours (Figure 3B).
For VHL, 67% (6 of 9) pathogenic variants observed off-tumour
were of germline origin whilst in the on-tumour setting this figure
was only 6% (5 of 86). This paradoxical observation is explained
by the high rate of somatic VHL mutation in renal cancers (79 of
82 tumour-detected pathogenic variants being somatic; supple-
mentary Figure S1, available at Annals of Oncology online).
Similarly, reflecting the high somatic APC mutation rate in colo-
rectal cancer (CRC), only 2 of 637 (0.3%) tumour-detected patho-
genic APC variants observed in CRC were of germline origin
(supplementary Figure S2, available atAnnals of Oncology online).
For the 27 standard actionability CSGs analysed, a >10% on-
tumour germline conversion rate was attained for genes BAP1,
FLCN, POLE and FH and a near 10% rate for CDKN2A (8.9%, 8
of 90) and NF1 (9 of 107, 8.4%). Notably intermediate pene-
trance genes CHEK2, ATM andHOXB13 also had a>10% germ-
line conversion rate (Figure 4).
Analyses of TP53: the most frequently somatically
mutated CSG
We went on to perform more in depth analysis of tumour-
detected TP53 pathogenic variants, on account of their high fre-
quency and the significant clinical implications of diagnosis of
Li-Fraumeni syndrome. Overall, 2930 tumour-detected TP53
Table 1. Summary of number of (i) tumour detected and (ii) true germline variants detected with application of (A) serial filters (B) gene/context/age crite-
ria, from data on 65 genes for 16 322 tumours (MSK dataset)
All tumours Associated tumours Non-associated
tumours
Tumour
detected
True
germline
Tumour
detected
True
germline
Tumour
detected
True
germline
(A) Application of
serial filters to
MSK data on 65
genes for 16 322
tumours: number
of variants
1 997 499 1 959 587
Retained:
MAF 0.01
79 342 53 388
Retained:
LP/P/truncating
17 075 1494
Retained: VAF
0.3 (SNV) or
0.2 (insdel)
All 9222 1442 2904 454 6305 983
HA-CSGs (AD) 6141 677 2259 326 3882 351
SA-CSGs (AD) 2372 213 539 37 1820 176
Other 709 547 106 91 603 456
(B) Application of
ESMO-PWG rec-
ommendations
for gene/context/
age criteria based
on 10% germline
conversion: num-
ber of variants
HA-CSGs (AD) all ages (18 genes) 851 615 410 300 441 315
age <30 (APC,
RB1)
63 10 37 4 26 6
age <30, on-tu-
mour only
(TP53)
59 7 59 7 n/a n/a
Total 973 632 506 311 467 321
SA-CSGs (AD) all ages, on tu-
mour only
(BAP1, FH, FLCN,
POLE),
60 17 60 17 n/a n/a
age <30, on tu-
mour only (NF1)
9 4 9 4 n/a n/a
Total 69 21 69 21 n/a n/a
Grand total 1042 653 575 332 467 321
HA-CSGs, high actionability genes; SA-CSGs, standard actionability CSGs; AD, autosomal dominantly inherited; other, CSGs of recessive inheritance, inter-
mediate penetrance and/or non-clinical grade actionability.
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pathogenic variants were detected across 16 322 tumours, with an
overall germline conversion rate of 1% (30/2930). This rate was
modestly higher in the on-tumour setting (2%, 16 of 786) than
off-tumour (0.7%, 14 of 2144) (supplementary Figure S3a, avail-
able at Annals of Oncology online). To explore whether enrich-
ment for germline origin was age-associated, we retained the
1273 tumours arising at age <30 years, in which there were 174
tumour-detected TP53 pathogenic variants. The distribution of
the 11 true germline variants amongst the 174 tumour-detected
TP53 pathogenic variants included 4 of 31 (12.9%) for breast can-
cers, 2 of 20 (10%) for soft tissue sarcomas, 1 of 7 (14.3%) for
bone tumours and 1 of 57 (1.8%) for gliomas and 3 of 60 (5%) in
non-associated tumours (supplementary Figure 3b, available at
Annals of Oncology online). The overall TP53 germline conversa-
tion rate in the on-tumour setting age<30 years was 6.8% (8 of
117), but with the exclusion of glioma, this rate was improved to
Figure 1. Distribution of variant allele frequency observed in the tumour for variants of true germline origin which were (i) small insertion/
deletions (ii) SNVs.
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Figure 2. Distribution of germline and somatic pathogenic variants detected upon tumour analysis. Only variants classified pathogenic/likely
pathogenic AND above VAF threshold are included (blue, germline origin; red, somatic origin; numbers, total number of pathogenic variants
observed in tumour).
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7 of 59 (11.7%). We also explored whether there was enrichment
of the TP53 germline conversation rate if only selected TP53muta-
tions were included but did not find evidence for this (supplemen-
tary Table S4, available atAnnals of Oncology online).
Analyses by patient age at tumour occurrence
Through restriction to tumours arising age<30 years, the overall
germline conversion rate was improved to >10% for high-
actionability genes RB1 (7 of 35, 20%) and APC (3 of 28, 10.7%),
and in the on-tumour context for the standard actionability gene
NF1 (4 of 9, 44.4%) (supplementary Figures S4 and S5, available
at Annals of Oncology online).
Examining further each individual gene for specific scenarios of
elevated germline conversion rate by each tumour type, and by all
ages, age<30 and age<5, we did not identify any additional scen-
arios in which a germline conversion rate of>10%was achieved.
Analyses in hypermutated samples
In separate analysis of the 830 samples in which the mutational
burden was above the 95th centile, the germline conversion rate
Figure 3. Distribution of germline and somatic pathogenic variants detected upon tumour analysis for 30 high-actionability CSGs. (A) Off-
tumour and (B) on-tumour.
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was>10% for the majority of HA-CSGs and notably all four mis-
match repair genes (MLH1, MSH2, MSH6, PMS2) (supplemen-
tary Figure S6, available at Annals of Oncology online). Of the 14
tumour-detected POLE pathogenic variants in these samples,
only one was of germline origin.
Summary of rate of detection of variants of true
germline origin
Overall, in our tumour-focussed germline analysis of the MSK
dataset, restricting firstly by VAF and secondly to the 27 genes
yielding germline conversion rate >10% as per specified gene/
context/age, the number of tumour-detected pathogenic variants
requiring ‘germline follow-up’ could be reduced by 94% from
17 075 to 1042 such that germline follow-up would only be
required in 6.4% of tumours (1042/16 322) (Table 1).
Of these 1042 variants, 653 (62.7%) were of true germline ori-
gin. These 653 pathogenic germline variants comprised 615
pathogenic variants detected age-unselected in HA-CSGs (300
on-tumour, 315 off-tumour), 17 on-tumour pathogenic variants
in BAP1/FH/FLCN/POLE, 7 on-tumour pathogenic TP53 var-
iants in tumours arising age<30 years and 14 pathogenic variants
in APC, RB1 andNF1 in tumours arising age<30 years.
Of the 689 true germline variants in dominant HA-CSGs
amongst the original 17 075 tumour-observed pathogenic var-
iants, 677 remain following VAF filtering and 45 are ‘thrown out’
via application of the 10% germline conversion gene/context/age
criteria [MEN1(4), PTEN(4), SMAD4(1), STK11(3) VHL(3),
TP53(23),APC(6), RB1(1)]. Of the 37 true germline variants aris-
ing on-tumour across SA-CSG genes, 21 are detected and 16 are
‘missed’. Overall, of the 789 (1442–653) true germline variants
that are ‘missed’, 547 are in genes acting recessively (namely
MUTYH), of intermediate penetrance and/or of non-clinical-
grade cancer association. A total of 176 variants are ‘missed’ be-
cause they occur off-tumour in SA-CSGs and we chose not to
identify them.
Discussion
Through our large-scale analysis of paired somatic/germline
data, the ESMO PMWG germline subgroup sought to develop
recommendations regarding germline-focussed analysis of
tumour-only sequencing data in order to optimise detection of
true germline variants in genes of clinical utility, whilst avoiding
excessive diversion of effort and resources towards ‘germline
follow-up testing’ of vast numbers of variants.
The first issue we explored was restriction based on VAF. For
this MSK dataset, we found that crude ‘pan-tumour’ VAF thresh-
olds (20% for small insertions/deletions, 30% for SNVs) enabled
reduction by almost half the number of tumour-detected variants
requiring follow-up (17 075 to 9222) whilst losing only a tiny
proportion of true germline variants (52 of 1494, 3.5%) and even
smaller proportion of variants in dominant HA-CSGs (12 of 689,
1.7%). This filter near doubles the germline conversion rate from
8.7% (1494 of 17 075) to 15.6% (1442 of 9222). However, the
VAFs used in this analysis may need to be re-evaluated by labora-
tories using PCR-based NGS methodologies rather than
hybridisation-based methods.
Next, to reduce further the number of variants requiring
follow-up, we recommend exclusion from germline-focussed tu-
mour analysis of gene/context/age scenarios in which the germ-
line conversion rate is <10%. Thus we highlight the 27 genes of
>10% germline conversion rate (Box 1). Following filters for
pathogenicity and VAF, restriction of germline-focussed tumour
analysis to just these 27 genes (as per gene/context/age
Figure 4. Distribution of germline and somatic pathogenic variants detected upon tumour analysis for non-high actionability CSGs in associ-
ated tumours (on-tumour).
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Box 1. Recommendations for genes to be included for germline-focussed analysis and triggering of germline sample laboratory confirmation
Any tumour type Associated tumour type only
Tumour arising any age BRCA1
BRCA2
BRIP1
MLH1
MSH2
MSH6
PALB2
PMS2
VHLa
RAD51C
RAD51D
RET
SDHA
SDHAF2
SDHB
SDHC
SDHD
TSC2
MUTYHb
FLCN
FH
BAP1
POLE
Tumour arising age <30 only RB1
APC
TP53c
NF1
aRenal tumours to be excluded.
bMUTYH should be included for germline-focussed tumour analysis but reporting and germline follow-up testing should only be performed on detection
of two pathogenic variants.
cBrain tumours to be excluded.
Recommendations, see also Box 1
1. Germline-focussed tumour analysis should be carried out in all laboratories as part of routine analysis of a large tumour panel.
2. Germline-focussed tumour analysis can be delivered via an automated pipeline so as not to add substantial additional manual work, cost or delay to
tumour analysis.
3. Variants in should be flagged which are (i) predicted to result in protein truncation in genes acting through loss-of-function and/or (ii) classified as
Pathogenic/Likely Pathogenic via a well-maintained, comprehensive and curated clinical resource (ClinVar is recommended).
4. Germline-focussed tumour analysis can be restricted to variants of VAF >30% (SNVs) or >20% (small insertions/deletions). Local validation will be required
to confirm the accuracy of tumour VAF estimates, especially for PCR-based NGS methodologies.
5. Samples known or suspected to be hypermutated should be included for germline-focussed tumour analysis.
6. Germline-focussed tumour analysis in the off-tumour context should be restricted to ‘High Actionability-CSGs’ (Box 1).
7. Recessively acting ‘High Actionability-CSGs’ (currently MUTYH alone) should be included for germline-focussed tumour analysis but reporting and germ-
line follow-up testing should be undertaken only on detection of two pathogenic variants.
8. Germline-focussed tumour analysis of ‘standard actionability’-CSGs should be restricted to the on-tumour setting.
9. ‘Standard actionability’-CSGs included for germline-focussed tumour analysis can be restricted to genes of high penetrance.
10. Germline-focussed tumour analysis can be restricted to gene-scenarios for which the germline conversion rate is >10%. For selected genes, it may
therefore be appropriate to restrict germline-focussed tumour analysis to just those tumours arising age <30 years.
11. Formal variant review and classification should be undertaken by an experienced clinical scientist before initiation of patient re-contact and/or germline
testing.
12. Before analysis of their germline sample for the pathogenic variant, adequate information should be provided to the patient regarding the implications of
germline testing, along with documentation of their consent.
13. The tumour-observed pathogenic variant should be analysed in an appropriate germline sample (lymphocytes, saliva/buccal swab, normal tissue) in a
laboratory accredited for germline analysis.
14. A patient in whom a germline pathogenic variant is detected should be referred to a specialist genetics service for long term follow-up and management
of the family.
15. A normal/negative tumour sequencing result should not be taken as equivalent to a normal/negative germline result unless robust analysis of dosage has
been carried out. This distinction is particularly important for genes such as BRCA1 and MSH2, for which whole exon deletion/duplications constitute a
substantial proportion of pathogenic variants.
16. Re-evaluation of this workflow, revised analyses and update of these recommendations should be undertaken at least 2-yearly. Reanalysis should
include updated data regarding pathogenicity of variants and penetrance of CSGs, along with review of thresholds for ‘germline conversion rates’ and
VAF cut-offs.
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recommendations) enables reduction by 88.7% of the number of
tumour observed variants requiring follow-up testing (from 9222
to 1042).
Although their germline conversion rate is high, we do not rec-
ommend germline-focussed tumour analysis for intermediate
penetrance genes, such as CHEK2 and ATM, as strategies are not
well agreed regarding management of risk within families. We
recognised nevertheless that in healthcare settings in which germ-
line analysis for these genes is routinely offered, there would be a
consistency in inclusion of these genes in germline-focussed tu-
mour analysis. Indeed, detection of CHEK2 c.1100delC may offer
greater clinical utility to the family when ascertained in an iso-
lated 60-year-old breast cancer case than in a multiplex breast
cancer family.
We recommend germline-focussed tumour analysis in the off-
tumour context is restricted to HA-CSGs, as per ACMG guidance
regarding return of secondary findings. Nevertheless, for some
genes on the ACMG secondary findings gene list, estimates are
highly uncertain regarding penetrance outside of phenotype-
driven ascertainment. Some centres may argue the merit of a nar-
rower set of HA-CSGs [27, 28]. For the remainder of genes (of
standard actionability) we recommended that germline-focussed
tumour analysis be restricted to the on-tumour setting, such that
germline pathogenic variants identified would be aetiologically
pertinent with regard to the tumour type in which they were
ascertained. For paediatric patients, special consideration will be
required regarding return of either (i) a germline pathogenic vari-
ant deemed causative of the early onset cancer, (ii) an off-tumour
pathogenic variant conferring risk only for adult onset cancers.
The germline conversion rates presented have been derived
from the MSK dataset. When applying these filters and criteria in
other settings, the frequency of germline variants detected will be
predicated on (i) the distribution of different tumour types, (ii)
the genes included on the panel, (iii) the purity of the tumours
and (iv) the accuracy of tumour VAF estimation. Furthermore, a
number of CSGs were not included on the MSK-IMPACT panel;
overall, the subgroup agreed that for these more ‘obscure’ CSGs,
whilst evaluation would be useful, these genes would at best be of
standard actionability and generally (i) the frequency/contribu-
tion to overall cancer susceptibility of pathogenic germline var-
iants is low (ii) the penetrance for cancer is poorly characterised
(iii) evidence is limited regarding the efficacy of clinical interven-
tions in carriers of pathogenic variants [20].
Local clinical workflows will need to evolve to encompass pa-
tient education, patient consent, acquisition of the germline sam-
ple and return of germline results. Some centres may elect as
routine to acquire a germline sample and provide up-front con-
sent to all individuals in whom tumour-only testing is carried out
(potentially as an ‘opt-out’). Alternatively, a two-stage approach
may be preferred, whereby germline consultation and acquisition
of the germline sample is only triggered on detection of a
tumour-detected pathogenic variant. Telephone consultation,
postal blood-packs and/or saliva sampling may mitigate other-
wise problematic increases in clinical workload associated with
this new burden of germline follow-up. If adjacent normal (or
tumour-poor) tissue is available, testing in this for the tumour-
detected pathogenic variant could provide a pragmatic means of
triaging out variants of low germline likelihood.
In conclusion, identification of a pathogenic variant in a CSG
can offer significant opportunity for the prevention and early de-
tection of future cancers in the patient as well as their family, and
may also influence management of the current cancer. Pragmatic,
strategic germline-focussed tumour analysis can offer a high yield
of true germline findings [63% true germline yield from follow-
up of 6.4% of tumours (MSK dataset)].
The remit of the current recommendations was to guide
germline-focussed tumour analysis of the tumour panels already
in current use. An urgent priority for debate by clinicians and
policy makers is consideration as to whether tumour panel con-
tent should be designed a priori to include genes selected for their
germline utility, not just for CSGs but perhaps also those relating
to pharmacogenomics.
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